Orchid Pharma Limited (ORCHPHARMA.NS)
INR 793.65
(-0.92%)
INR 793.65
(-0.92%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.19 Billion INR | 23.05% |
| 2022 | 6.65 Billion INR | 19.0% |
| 2021 | 5.59 Billion INR | 24.33% |
| 2020 | 4.5 Billion INR | -11.41% |
| 2019 | 5.08 Billion INR | -15.32% |
| 2018 | 5.99 Billion INR | -12.15% |
| 2017 | 6.82 Billion INR | -13.36% |
| 2016 | 7.88 Billion INR | -9.66% |
| 2015 | 8.72 Billion INR | -25.07% |
| 2014 | 11.64 Billion INR | -10.32% |
| 2013 | 12.98 Billion INR | 5.75% |
| 2012 | 12.27 Billion INR | -31.49% |
| 2011 | 17.92 Billion INR | 0.59% |
| 2010 | 17.81 Billion INR | 32.63% |
| 2009 | 13.43 Billion INR | 3.59% |
| 2008 | 12.96 Billion INR | -0.32% |
| 2007 | 13 Billion INR | 34.98% |
| 2006 | 9.63 Billion INR | 2.9% |
| 2005 | 9.36 Billion INR | 29.67% |
| 2004 | 7.22 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.44 Billion INR | 12.58% |
| 2023 FY | 8.19 Billion INR | 23.05% |
| 2023 Q1 | 1.82 Billion INR | -12.85% |
| 2023 Q2 | 1.98 Billion INR | 8.66% |
| 2023 Q3 | 2.2 Billion INR | 10.99% |
| 2023 Q4 | 2.17 Billion INR | -1.58% |
| 2022 FY | 6.65 Billion INR | 19.0% |
| 2022 Q4 | 2.09 Billion INR | 31.38% |
| 2022 Q1 | 1.3 Billion INR | -26.47% |
| 2022 Q2 | 1.65 Billion INR | 26.16% |
| 2022 Q3 | 1.59 Billion INR | -3.32% |
| 2021 Q4 | 1.78 Billion INR | 10.38% |
| 2021 Q1 | 923.12 Million INR | -22.79% |
| 2021 FY | 5.59 Billion INR | 24.33% |
| 2021 Q2 | 1.27 Billion INR | 38.37% |
| 2021 Q3 | 1.61 Billion INR | 26.34% |
| 2020 FY | 4.5 Billion INR | -11.41% |
| 2020 Q4 | 1.19 Billion INR | 16.32% |
| 2020 Q3 | 1.02 Billion INR | -5.31% |
| 2020 Q2 | 1.08 Billion INR | -8.9% |
| 2020 Q1 | 1.19 Billion INR | 6.85% |
| 2019 Q1 | 1.35 Billion INR | 0.0% |
| 2019 FY | 5.08 Billion INR | -15.32% |
| 2019 Q4 | 1.11 Billion INR | -13.86% |
| 2019 Q2 | 1.31 Billion INR | -2.8% |
| 2019 Q3 | 1.29 Billion INR | -1.65% |
| 2018 Q2 | 1.42 Billion INR | 0.0% |
| 2018 FY | 5.99 Billion INR | -12.15% |
| 2017 Q2 | 2.09 Billion INR | 0.0% |
| 2017 FY | 6.82 Billion INR | -13.36% |
| 2016 FY | 7.88 Billion INR | -9.66% |
| 2015 FY | 8.72 Billion INR | -25.07% |
| 2015 Q1 | 2.56 Billion INR | 0.0% |
| 2014 FY | 11.64 Billion INR | -10.32% |
| 2013 Q2 | 3.77 Billion INR | 0.0% |
| 2013 FY | 12.98 Billion INR | 5.75% |
| 2012 Q4 | 2.68 Billion INR | 0.0% |
| 2012 Q2 | 3.3 Billion INR | 0.0% |
| 2012 FY | 12.27 Billion INR | -31.49% |
| 2011 Q4 | 4.51 Billion INR | 0.0% |
| 2011 FY | 17.92 Billion INR | 0.59% |
| 2010 FY | 17.81 Billion INR | 32.63% |
| 2009 FY | 13.43 Billion INR | 3.59% |
| 2008 FY | 12.96 Billion INR | -0.32% |
| 2007 FY | 13 Billion INR | 34.98% |
| 2006 FY | 9.63 Billion INR | 2.9% |
| 2005 FY | 9.36 Billion INR | 29.67% |
| 2004 FY | 7.22 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sigachi Industries Limited | 3.98 Billion INR | -105.378% |
| Ind-Swift Limited | 5.02 Billion INR | -63.069% |
| Innova Captab Limited | 10.81 Billion INR | 24.224% |
| Aarti Drugs Limited | 25.28 Billion INR | 67.596% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 54.868% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -73.075% |
| Sakar Healthcare Limited | 1.54 Billion INR | -431.48% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 97.175% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 33.836% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 36.754% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -123.046% |
| Morepen Laboratories Limited | 17.01 Billion INR | 51.856% |
| Sequent Scientific Limited | 13.69 Billion INR | 40.18% |
| Wanbury Limited | 5.75 Billion INR | -42.338% |
| Laurus Labs Limited | 50.01 Billion INR | 83.619% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 51.36% |
| Gufic Biosciences Limited | 8.06 Billion INR | -1.575% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 64.113% |
| Alembic Limited | 1.57 Billion INR | -420.282% |
| Hikal Limited | 17.84 Billion INR | 54.087% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 86.594% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 93.064% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 61.582% |
| Themis Medicare Limited | 3.81 Billion INR | -114.629% |
| RPG Life Sciences Limited | 5.82 Billion INR | -40.773% |
| Lupin Limited | 196.56 Billion INR | 95.832% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -94.518% |
| Wockhardt Limited | 27.89 Billion INR | 70.621% |
| Vaishali Pharma Limited | 862.79 Million INR | -849.665% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -292.602% |
| NATCO Pharma Limited | 40.02 Billion INR | 79.526% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 87.776% |
| FDC Limited | 19.42 Billion INR | 57.829% |
| Divi's Laboratories Limited | 78.45 Billion INR | 89.556% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -430.773% |
| Eris Lifesciences Limited | 20.09 Billion INR | 59.218% |
| Windlas Biotech Limited | 6.3 Billion INR | -29.861% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 98.31% |
| Mankind Pharma Limited | 103.34 Billion INR | 92.072% |
| Venus Remedies Limited | 5.91 Billion INR | -38.536% |
| ZIM Laboratories Limited | 3.67 Billion INR | -122.947% |
| Neuland Laboratories Limited | 15.58 Billion INR | 47.429% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 76.234% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | -41.137% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 95.692% |
| Bal Pharma Limited | 3.39 Billion INR | -141.545% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 97.065% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -756.718% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 51.134% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -6.378% |
| Shilpa Medicare Limited | 11.53 Billion INR | 28.943% |
| Albert David Limited | 3.62 Billion INR | -126.056% |
| Ajanta Pharma Limited | 42.08 Billion INR | 80.532% |
| Hester Biosciences Limited | 3.04 Billion INR | -169.046% |
| Valiant Laboratories Limited | 1.82 Billion INR | -350.061% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 22.065% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 28.829% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -107.111% |
| Granules India Limited | 45.06 Billion INR | 81.818% |
| Alkem Laboratories Limited | 126.67 Billion INR | 93.532% |
| Medicamen Biotech Limited | 1.79 Billion INR | -356.966% |
| Unichem Laboratories Limited | 16.57 Billion INR | 50.564% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -437.411% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1946.614% |
| Medico Remedies Limited | 1.44 Billion INR | -465.391% |
| Ipca Laboratories Limited | 77.05 Billion INR | 89.367% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -216.061% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 36.032% |
| Brooks Laboratories Limited | 794.86 Million INR | -930.832% |
| Piramal Enterprises Limited | 60.33 Billion INR | 86.42% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 92.274% |
| Suven Life Sciences Limited | 116.92 Million INR | -6907.399% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -1525.037% |
| Strides Pharma Science Limited | 40.51 Billion INR | 79.774% |
| Indoco Remedies Limited | 18.17 Billion INR | 54.913% |
| Alpa Laboratories Limited | 1.08 Billion INR | -653.518% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -685.324% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -984.605% |